TL;DR
Through an in-depth analysis of IL- and IFN-associated clinical trials, this article has highlighted their promising potential in the treatment of ovarian cancer through the utilization of type-I IFN and type-II IFN.
AI-generated by Semantic Scholar
Authors
Huldani Huldani, Sana Abdul-Jabbar Ali, F. Al-dolaimy, Ahmed Hjazi, Nikolenko Denis Andreevich, Khulood H. Oudaha, Abbas F. Almulla, Ali Alsaalamy, Shamam Kareem Oudah, Yasser Fakri Mustafa